Skip to main content

Table 1 Bioluminescence intensity levels emitted in different body sections of mice along the experimental time

From: An Auristatin nanoconjugate targeting CXCR4+ leukemic cells blocks acute myeloid leukemia dissemination

  

Day after i.v. injection of cells

Treatment

1

4

6

8

11

12

13

Full body

VEH

6.61E+05

7.91E+05

1.29E+06

3.76E+06

2.95E+07

4.37E+07

6.44E+07

T22-AUR

6.33E+05

8.43E+05

1.25E+06

1.65E+06

1.22E+07

1.92E+07

2.96E+07

 

p value

0.4624

0.5675

0.3904

0.0002

0.0003

0.0002

0.0002

Hindlimbs section (bone marrow)

VEH

2.03E+05

2.80E+05

4.94E+05

1.57E+06

1.54E+07

2.21E+07

2.93E+07

T22-AUR

1.95E+05

3.01E+05

4.67E+05

7.20E+05

8.34E+06

1.25E+07

1.80E+07

 

p value

0.4375

0.4377

0.1777

0.0002

0.0043

0.0009

0.0033

Abdominal section (extramedullar)

VEH

1.94E+05

2.51E+05

4.76E+05

1.51E+06

9.13E+06

1.52E+07

2.70E+07

T22-AUR

1.77E+05

2.88E+05

4.44E+05

5.39E+05

1.41E+06

2.45E+06

4.70E+06

 

p value

0.2699

0.1651

0.5401

0.0002

0.0002

0.0002

0.0002

  1. Levels of luminescence detected using the IVIS Spectrum in mice treated with vehicle (VEH) or T22-GFP-H6-Auristatin in full body, hindlimbs section (bone marrow), and in abdominal section (including liver and spleen) of mice during the experiment. Results are presented by mean total flux [photons/second] of radiance detected in mice for each group. U of Mann-Whitney test was used to assess the significance of the differences between groups. These differences were considered statistically significant when the p value was lower than 0.05 (bold values)
  2. BLI bioluminescence, i.v. intravenously, T22-AUR T22-GFP-H6-Auristatin group, VEH vehicle group
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us